Phase Ⅲ Study of Bevacizumab plus Docetaxel Compared with Placebo plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
1Miller K, Wang M, Gralow J, et al. Paclitaxel plus Bevacizumab versus Paclitaxel alone for metastatic breast caneer[J]. N Engl J Med, 2007,357(26):2666-2676.
2Miles DW, Chan A, Dirix LY, et al. Phase Ⅲ study of Bevacizumab plus Docetaxel compared with placebo plus Docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer[J]. J Clin Oneol, 2010,28 (20) : 3239-3247.
3Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1 : Randomized, double-blind, placebo-controBed, phase Ⅲ trial of chemotherapy with or without Bevacizumab for first-line treatment of human epidermal growth factor receptor 2- negative, locally recurrent or metastatic breast cancer [J]. J Clin Oncol, 2011,29(10) : 1252-1260.
4O'Shaughnessy JA, Brufsky AM. RIBBON 1 and RIBBON 2: phase Ⅲ trims of Bevacizumab with standard chemotherapy for metastatic breast cancer [J]. Clin Breast Cancer, 2008,8(4): 370-373.
5Brufsky AM, Hurvitz S, Perez E, et al. RIBBON-2: A randomized, double-blind, placebo-controlled, phase Ⅲ trial evaluating the efficacy and safety of Bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer [Jl. J Clin Oneol, 2011,29(32) :4286-4293.
6von Minckwitz G, Eidtmann H, Rezai M, et al. Neoadjuvant chemotherapy and Bevacizumab for HER2-negative breast cancer[J]. N Engl J Med, 2012,566(4):299-309.
